Ph 2 Bortezomib, Dexamethasone, + Doxorubicin With ALCAR for Previously Treated Multiple Myeloma
Status:
Completed
Trial end date:
2013-07-01
Target enrollment:
Participant gender:
Summary
Patients will receive Bortezomib, Dexamethasone, and Doxorubicin in 21 day cycles a total of
4 to 8 times (based on response to the treatment). Patients will also receive
acetyl-L-carnitine (ALCAR) daily.